SENSOME

Sensome operates at the intersection of medical devices, embedded systems, and clinical technology. Its stated differentiation is to add micro-sensors and biological tissue characterization to devices used in vascular procedures, rather than relying only on conventional imaging to infer what a device is contacting. The Clotild platform applies impedance-based sensing and machine-learning or predictive methods to clot characterization during thrombectomy, while the company’s reported first-in-human lung tumor-detection work suggests an effort to extend the underlying approach into another clinical setting. Its strategic relationship with ASAHI INTECC, a guidewire manufacturer, is relevant to device design and potential manufacturing and distribution. Sensome has disclosed a five-round financing history totaling about $18.9 million and had a Series B in January 2020, placing its disclosed funding history behind the 2026 clinical updates. Its competitive standing will depend on clinical validation, regulatory progress, and whether sensing information improves procedural decisions over existing approaches.

Sensome’s trajectory reflects a long development cycle from early financing toward clinical testing. It was founded in 2014 and raised three early rounds between February 2015 and July 2017, followed by a $5.4 million Seed round in June 2018 and an $8.9 million Series B in January 2020. Across five rounds, disclosed funding totals approximately $18.9 million; no later financing is listed. The 2026 milestones mark an important shift in evidence generation: the Clotild Smart Guidewire System was used in first-in-human procedures in the CLOT OUT study, and a May 4 study publication reported clot-composition findings in fully occluded brain vessels. On May 19, the company announced positive first-in-human results for an investigational in-situ lung tumor-detection technology, broadening the potential applications of its sensing platform. The ASAHI INTECC partnership provides a route to guidewire design, manufacturing, and distribution, though commercial availability is not established by these announcements. A 2025 placement of a senior medical-device R&D leader is another indication of development capacity. Overall, clinical results—not recent fundraising or disclosed headcount growth—are the clearest visible inflection points.